Lenvatinib in advanced thyroid, salivary gland, endometrial, and hepatocellular carcinomas: a real-world study on treatment duration and toxicity management
Despite the higher prevalence of elderly subjects and ECOG PS 2, our series confirmed the long-term manageability and effectiveness of LEN in the real world. Patients with a baseline low BMI require special attention, as LEN treatment can be implicated in further BW decrease.
Authors
- Francesco Raspagliesi (ORCID: https://orcid.org/0000-0001-8953-1657)
- Imperia Nuzzolese (ORCID: https://orcid.org/0000-0001-6293-5301)
- Monika Ducceschi
- Marta Bini (ORCID: https://orcid.org/0000-0001-6147-2587)
- Alessandra Russo (ORCID: https://orcid.org/0000-0002-6304-7928)
- Giulia Montelatici
- Cristiana Bergamini (ORCID: https://orcid.org/0000-0001-7616-5125)
- Elena Colombo (ORCID: https://orcid.org/0000-0003-3132-844X)
- Lisa Francesca Licitra (ORCID: https://orcid.org/0000-0003-0623-4118)
- Valentina Bellia
- Sherrie Bhoori (ORCID: https://orcid.org/0000-0002-2837-6398)
- Vincenzo Mazzaferro (ORCID: https://orcid.org/0000-0002-4013-8085)
- Arianna Ottini (ORCID: https://orcid.org/0000-0003-4239-8072)
- Paolo Ambrosini
- Salvatore Alfieri (ORCID: https://orcid.org/0000-0001-8485-2275)
- Stefano Cavalieri (ORCID: https://orcid.org/0000-0003-1294-6859)
- Mara Mantiero (ORCID: https://orcid.org/0000-0002-1016-4995)
- Maggie Polignano
- Matteo De Monte
Institutions
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
Publication Details
- Journal
- Therapeutic Advances in Medical Oncology
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1177/17588359251359905
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00